GLOBEALERT
Business● LowSep 21 · Sep 21, 2026, 10:00 AM

Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts

GlobeAlert Desk · curated from South China Morning Post · global

US-China biotech deals are expected to thrive because Washington is reportedly leaning away from sweeping restrictions, according to analysts, giving Chinese healthcare firms a major boost following Beijing’s ambitious five-year plan for the sector. Out-licensing deals between China and the US would “ride on a high tide” in the favourable environment, said Nomura’s head of China healthcare research Jialin Zhang, in a research note on Sunday. The US Treasury Department was drafting investment...

GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text. How we score stories.

GlobeAlert context

What the desk knows about this story

Threat level
1 Low

Scored from severity, scale, escalation potential and source agreement. Below the alert threshold.

Sources
1 publisher

Single-source so far. Treat details as unconfirmed until more publishers report.

Category
Business

Not flagged as developing.

More in Business

Expect ‘high tide’ of Chinese biotech deals as threat of US curbs fades: analysts · GlobeAlert